BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements

Dow Jones

05/21

By Christopher Kuo

BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants.

The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature.

The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span.

The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 20, 2026 16:57 ET (20:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2637136875"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637136875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637136875?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 04:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637136875","market":"hk","top_or_hot":-1,"title":"BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n</p>\n<p>\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n</p>\n<p>\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n</p>\n<p>\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2026 16:57 ET (20:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-21 04:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n</p>\n<p>\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n</p>\n<p>\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n</p>\n<p>\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2026 16:57 ET (20:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2637136875","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637136875","pubTimestamp":1779310620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants.The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature.The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span.The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BMRN":"拜玛林制药","BK4566":"资本集团","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"BioMarin表示Voxzogo的3期研究显示患者有所改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n\n\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n\n\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n\n\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 16:57 ET (20:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}